Tokyo, Sept. 13 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058981) titled 'Internet survey on the prevalence of constipation in patients with schizophrenia and depression - CONSIDER survey' on Sept. 12.
Study Type:
Observational
Primary Sponsor:
Institute - EA Pharma Co., Ltd.
Condition:
Condition - schizophrenia, depression
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - Constipation is a common gastrointestinal disorder that impairs quality of life, and it has been reported to frequently complicate with schizophrenia and depression. An online survey will be conducted to investigate the prevalence of constipation, its severity, its impact on quality of life, and treatment status among patients with schizophrenia and depression.
Basic objectives2 - Others
Eligibility:
Age-lower limit - Not applicable
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - People with schizophrenia or depression, as well as members of the general public, who are registered with Cross Marketing Inc.'s research cooperation panel and have agreed to participate in this survey.
Key exclusion criteria - Nothing in particular
Target Size - 800
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2025 Year 08 Month 21 Day
Anticipated trial start date - 2025 Year 10 Month 01 Day
Last follow-up date - 2025 Year 10 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067342
Disclaimer: Curated by HT Syndication.
